Major Depressive Disorder Clinical Trials in Tampa, Florida

9 studies are recruiting for major depressive disorder in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Tampa, Florida

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Interventional Psychiatry of Tampa Bay, Tampa, Florida

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

3. NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Tampa, Florida

   Locations

   39 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06911112 on ClinicalTrials.gov

4. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Tampa, Florida

   Locations

   35 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963021 on ClinicalTrials.gov

5. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   K2 Medical Research (Tampa), Tampa, Florida

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

6. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Tampa, Florida

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

7. A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Tampa, Florida

   Locations

   60 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07196501 on ClinicalTrials.gov

8. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

   The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Autobahn Site #148, Tampa, Florida

   Locations

   50 in total

   Run by

   Autobahn Therapeutics, Inc.

   See if you can join NCT06633016 on ClinicalTrials.gov

9. Study of ALTO-300 in MDD

   The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Site 221, Tampa, Florida

   Locations

   45 in total

   Run by

   Alto Neuroscience

   See if you can join NCT05922878 on ClinicalTrials.gov